hi tbs, good news, that china-price shall more than likely happen to outrageously expensive bio-medicine, per protocol of following and leapfrogging any and all self-annointed leaders
enabling more than just the 1% to enjoy what science can tee-up
creative destruction - gotta love it
bloomberg.com
China's Great Leap Into BiotechWinners are emerging as Beijing backs cheaper -- better? -- treatments.
More stories by Shuli RenJanuary 18, 2018, 3:00 AM GMT+8
Cutting-edge cures
China wants to go big on biotech and already is marching into experimental gene therapy.
Last year marked a milestone in cancer treatment: In August, the U.S. FDA approved Novartis AG's Kymriah, a CAR-T 1 therapy for children with acute lymphoblastic leukemia, a blood and bone-marrow cancer previously considered untreatable. Two months later, Kite Pharma Inc.'s Yescarta, which also uses CAR-T to target certain types of large B-cell lymphoma in adults, got the green light, too.
So far, CAR-T has shown extraordinary results. More than 60 percent of children treated with Kymriah were cured, while the rate of full remission for patients treated with Yescarta was more than half.
The big problem is price. Kymriah costs $475,000 for a single treatment; Yescarta goes for $373,000.
Now China reckons it can do this better and cheaper. There are currently 153 CAR-T studies in the nation, just behind 186 in the U.S., according to Bernstein Research's Laura Nelson Carney. Already, China has one therapy commercially available in a free-trade zone for medical tourism on the resort island of Hainan. The product, made by Innovative Cellular Therapeutics Co., sells for 490,000 yuan ($76,000) per treatment. Prices for CAR-T can be expected to drop below 100,000 yuan in three years, according to local media reports.
It's not hard to see the potential. For one thing, China's huge population means an abundance of patients for trials. For another, the nation is now flooded with venture-capital money to throw at well-qualified " sea turtles" -- as returning Chinese expats are known -- to build world-class medical labs at home.
Heating UpChina saw a spike in biotech private equity deals in the last two years. And 2018 is starting nicely
Source: Bloomberg
Note: For comparison purposes, the U.S. had $7.9 billion PE/VC deals in biotech last year.
Beijing is keen to leapfrog. On Dec. 20, just one week after Nanjing Legend Biotechnology Co. applied to the Center for Drug Evaluation -- China's equivalent of the FDA -- for CAR-T clinical trials, the regulator placed the treatment on its priority review list. That's a prelude to approval.
Nanjing Legend is being fast-tracked because it grabbed attention at the American Society of Clinical Oncology's annual meeting last June with good trial results for a multiple-myeloma treatment. Nanjing's CAR-T was seen as on par with products from Celgene Corp. and Bluebird Bio Inc., according to Bloomberg Intelligence analyst Curt Wanek.
Underlining Nanjing Legend's progress, Johnson & Johnson in December entered a joint venture with the firm, paying $350 million upfront and promising to share half the profits.
All this buoyed Nanjing Legend's parent, Hong Kong-listed Genscript Biotech Corp. The company went public two years ago with an unimpressive offering of HK$524 million ($67 million), then soared 580 percent over the last year to become a $5 billion mid-cap.
Smelling profit and prestige, Hong Kong Exchanges & Clearing Ltd. has proposed letting biotech companies list without track records of profitability. Of its more than 2,100 current listings, only 47 are in biotech or pharmaceuticals, so investors are likely to appreciate the newcomers.
Wuxi Biologics Cayman Inc., which leverages China's army of cheap lab technicians for contract biotech research on behalf of global pharmaceutical makers, helped set a track record by soaring 164 percent since its HK$4.6 billion IPO last June.
Buyer beware, though: Scarcity doesn't come cheap. Wuxi Biologics is now trading at 152 times forward earnings, with only 50 percent top-line growth expected this year.
The valuation of Genscript Biotech is more nuanced. According to Bernstein estimates, the entire Chinese market into which the company can sell, assuming $76,000 per treatment and 1 percent penetration -- even at that price, CAR-T is expensive -- is only $6 billion. 2 Genscript's $5 billion market cap pretty much assumes regulatory approval and a monopoly position in multiple-myeloma gene therapies.
With most of these therapies, the scale of potential markets is the big question. Pricing aside, will Chinese patients accept the notion of genetically altered cells? They may not be fans of genetically modified food, viewing it as an unnecessary risk to health. But when taking that risk is the only way to save lives, attitudes can change quickly.
This column does not necessarily reflect the opinion of Bloomberg LP and its owners.
Chimeric antigen receptor T-cell therapy, known as CAR-T, uses a patient's own immune system to battle cancer. Doctors remove T-cells -- bounty hunters of the immune system -- from a patient's body and genetically alter them to fight tumor cells. Then these supercharged T-cells are grown by the millions and injected back into the patient's body to kill cancer.
China's occurrence of multiple myeloma is 0.4 cases per 100,000 people.
To contact the author of this story:
Shuli Ren in Hong Kong at sren38@bloomberg.net
To contact the editor responsible for this story:
Paul Sillitoe at psillitoe@bloomberg.net
Before it's here, it's on the Bloomberg Terminal. LEARN MORE
Shuli Ren is a Bloomberg Gadfly columnist covering Asian markets. She previously wrote on markets for Barron's, following a career as an investment banker, and is a CFA charterholder. |
